1. (Amended) A pharmaceutical composition which comprises orlistat and a pharmaceutically acceptable bile acid sequestrant selected from the group consisting of DEAE-cellulose, guanidinoethylcellulose, and DEAE-Sephadex.

8. (Amended) The composition according to claim 10, wherein pharmaceutically acceptable bile acid sequestrant is selected from the group consisting of β-cyclodextrin and γ-cyclodextrin.

10. (Amended) A pharmaceutical composition which comprises orlistat and a pharmaceutically acceptable acid sequestrant selected form the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β-cyclodextrin, and γ-cyclodextrin.

17. (Amended) The composition according to claim 1, wherein the composition comprises (a) from about 5 to about 1000 mg of orlistat and (b) from about 0.1 to about 20 g of the bile acid sequestrant.

18. (Amended) The composition according to claim 17, which comprises:

(a) from about 5 to about 1000 mg of orlistat;

(b) from about 0.1 to about 20 g bile acid sequestrant selected from the group consisting of DEAE-cellulose, guanidinoethylcellulose, and DEAE-Sephadex;

(c) from about 0.1 to about 10 g of a filler;

(d) from about 0.05 to about 3.0 g of a surfactant;

(e) from about 0.05 to about 2.0 g of a disintegrant;

(f) from about 0.02 to about 2.0 g of a binder;

(g) from about 0.001 to about 1.0 g of a lubricant;

(h) from about 0.1 to about 5.0 g of a flowability enhancer;

(i) from about 0.01 to about 4.0 g of a sweetener; and

(j) and about 0.001 to about 0.5 g of a colorant.

27. (Amended) A kit for use in the treatment of obesity, which comprises (a) a first component which is orlistat and (b) a second component which is a bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex, present in oral unit dosage form.

28. (Amended) A method of treating obesity in an obese patient, which comprises administering to a patient in need of such treatment (a) a therapeutically effective amount of orlistat and (b) a pharmaceutically acceptable bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex in an amount effective to reduce gastrointestinal side effects associated with the lipase inhibitor.

32. (Amended) A method of reducing the gastrointestinal side effects associated with orlistat treatment, which comprises administering to a patient being treated with orlistat an amount of a bile salt sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-

cellulose, β- cyclodextrin, γ-cyclodextrin, guanidinoethylcellulose, and DEAE-Sephadex, effective to reduce the side effects associated with the orlistat treatment. --

33. (New) The composition according to claim 10, wherein the composition comprises (a) from about 5 to about 1000 mg of orlistat and (b) from about 0.1 to about 20 g of the bile acid sequestrant. --

34. (New) The composition according to claim 33, which comprises:

(a) from about 5 to about 1000 mg of orlistat;

(b) from about 0.1 to about 20 g bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, and γ-cyclodextrin;

(c) from about 0.1 to about 10 g of a filler;

(d) from about 0.05 to about 3.0 g of a surfactant;

(e) from about 0.05 to about 2.0 g of a disintegrant;

(f) from about 0.02 to about 2.0 g of a binder;

(g) from about 0.001 to about 1.0 g of a lubricant;

(h) from about 0.1 to about 5.0 g of a flowability enhancer;

(i) from about 0.01 to about 4.0 g of a sweetener; and

(j) and about 0.001 to about 0.5 g of a colorant.

35. (New) The composition according to claim 13, wherein the composition comprises (a) from about 5 to about 1000 mg of orlistat and (b) from about 0.1 to about 20 g of the bile acid sequestrant.

-- 36. (New) The composition according to claim 35, which comprises:

(a) from about 5 to about 1000 mg of orlistat;

(b) from about 0.1 to about 20 g bile acid sequestrant selected from the group consisting of cholestyramine, colestipol, colestimide, colesevelam, sevelamer, DEAE-cellulose, β- cyclodextrin, and γ-cyclodextrin;

(c) from about 0.1 to about 10 g of a filler;

(d) from about 0.05 to about 3.0 g of a surfactant;

(e) from about 0.05 to about 2.0 g of a disintegrant;

(f) from about 0.02 to about 2.0 g of a binder;

(g) from about 0.001 to about 1.0 g of a lubricant;

(h) from about 0.1 to about 5.0 g of a flowability enhancer;

(i) from about 0.01 to about 4.0 g of a sweetener; and

(j) and about 0.001 to about 0.5 g of a colorant. --

-- 37. (New) The compositions according to claim 33, wherein the orlistat is present in an amount of from about 10 to about 500 mg. --

-- 38. (New) The composition according to claim 37, wherein the orlistat is present in an amount of about 120 mg. --

-- 39. (New) The composition according to claim 33, wherein the orlistat is present in an amount of from about 20 to about 100 mg. --

-- 40. (New) The composition according to claim 39, wherein the orlistat is present in an amount of about 60 mg. --

-- 41. (New) The composition according to claim 33, wherein the bile acid sequestrant is present in an amount of from about 0.5 to about 10 g. --

-- 42. (New) The composition according to claim 41, wherein the bile acid sequestrant is present in an amount of from about 1 to about 5 g. --

-- 43. (New) The compositions according to claim 35, wherein the orlistat is present in an amount of from about 10 to about 500 mg. --

-- 44. (New) The composition according to claim 43, wherein the orlistat is present in an amount of about 120 mg. --

-- 45. (New) The composition according to claim 43, wherein the orlistat is present in an amount of from about 20 to about 100 mg. --

-- 46. (New) The composition according to claim 45, wherein the orlistat is present in an amount of about 60 mg. --

-- 47. (New) The composition according to claim 35, wherein the bile acid sequestrant is present in an amount of from about 0.5 to about 10 g. --

-- 48. (New) The composition according to claim 47, wherein the bile acid sequestrant is present in an amount of from about 1 to about 5 g. --